DAMORA THERAPEUTICS, INC. Income Taxes Receivable, Noncurrent
DAMORA THERAPEUTICS, INC. (DMRA) had Income Taxes Receivable, Noncurrent of $856.00 thousand as of 2021-09-30, per its 10-Q filed 2021-11-04.
Discontinued › Notes
us-gaap:IncomeTaxesReceivableNoncurrent · last filed 2021-11-04
- 2021-09-30: Income Taxes Receivable, Noncurrent $856.00K.
- 2021-06-30: Income Taxes Receivable, Noncurrent $876.00K.
- 2021-03-31: Income Taxes Receivable, Noncurrent $868.00K.
- 2020-09-30: Income Taxes Receivable, Noncurrent $865.00K.
| Period end | Income Taxes Receivable, Noncurrent |
|---|---|
| 2021-09-30 | $856.00K 10-Q · filed 2021-11-04 |
| 2021-06-30 | $876.00K 10-Q · filed 2021-08-05 |
| 2021-03-31 | $868.00K 10-Q · filed 2021-05-04 |
| 2020-09-30 | $865.00K 10-Q · filed 2020-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |